Courtesy of Dr. Carlos Fava. The real incidence of peripheral artery (PAD) disease in TAVR remains unclear. Different reports still estimate it is between 10 and 46%, but they have shown it has a negative impact in evolution. 51,685 TAVR patients were analyzed. 12,740 of these patients presented PAD (24.6%). PAD patients tended to be<a href="https://solaci.org/en/2019/09/11/the-real-impact-of-peripheral-artery-disease-in-tavr/" title="Read more" >...</a>
Data from a great Australian registry of nearly 250,000 people with a 5-year follow-up, presented at the European Society of Cardiology (ESC) Congress 2019 in Paris and simultaneously published in J Am Coll Cardiol, suggest that mortality due to severe aortic stenosis is similar to that due to moderate aortic stenosis. These data warn us<a href="https://solaci.org/en/2019/09/10/esc-2019-how-benign-is-moderate-aortic-stenosis/" title="Read more" >...</a>
Negative one-year outcomes of Mitra-FR led to several discussions and hypothesis, especially after the COAPT was published only a few weeks later. According to the COAPT study, the MitraClip was able to reduce hospitalization rate for cardiac failure and also all-cause mortality, compared against optimal medical treatment alone. When comparing the COAPT to the Mitra-FR,<a href="https://solaci.org/en/2019/09/06/esc-2019-mitra-fr-2-year-outcomes-of-one-of-the-largest-studies-on-mitraclip/" title="Read more" >...</a>
This new consensus published this week in J Am Coll Cardiol has provided us with an algorithm to manage conduction disturbances after transcatheter aortic valve replacement. This consensus is intended to reduce potential deaths caused by conduction disturbances and, at the same time, reduce unnecessary definite pacemaker implantation. This document is a big step ahead<a href="https://solaci.org/en/2019/09/04/experts-reach-consensus-on-post-tavr-pacemaker-indication/" title="Read more" >...</a>
After the recent announcement by the US Food and Drug Administration (FDA) green-lighting transcatheter aortic valve replacement (TAVR) in patients across the whole spectrum, and given the advancements regarding devices already in the market (such as MitraClip) and a variety of pulmonary valves, there is only one territory left to conquer: the long forgotten tricuspid<a href="https://solaci.org/en/2019/08/30/physiological-and-clinical-changes-after-tricuspid-repair/" title="Read more" >...</a>
This new strategy to reduce the risk of stroke in patients with atrial fibrillation is technically feasible and safe, even though long-term outcomes are yet to be seen and despite the evidence available, for instance, left atrial appendage closure devices. It is true that they could be used simultaneously, but its synergy and cost have<a href="https://solaci.org/en/2019/08/29/permanent-carotid-coil-filters-in-patients-with-atrial-fibrillation/" title="Read more" >...</a>
Patients with isolated tricuspid regurgitation (i.e., who have no associated left-sided valve disease) are frequently treated conservatively. In many cases, valve disease is highly symptomatic, even with the optimization of medical treatment; however, an invasive strategy is seldom proposed. The aim of this work was to measure the impact of surgery on isolated tricuspid regurgitation<a href="https://solaci.org/en/2019/08/26/surgery-to-improve-survival-in-isolated-tricuspid-regurgitation/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15% according to different reports and, so far, no one has analyzed in depth whether new oral anticoagulant agents (non-vitamin K oral anticoagulants [NOACs]) result in superior benefit compared with classic vitamin K antagonists (VKAs). This study analyzed<a href="https://solaci.org/en/2019/08/23/do-noacs-result-in-any-benefit-in-tavr/" title="Read more" >...</a>
Both the self-expandable valve Evolut R and its direct competitor, balloon-expandable valve Sapien 3, received the authorization to be indicated for low-risk patients in a long-awaited announcement made on August 16th, 2019. The US Food and Drug Administration (FDA) has approved and expanded the indication for the Evolut series (Medtronic) and the Sapien 3 and<a href="https://solaci.org/en/2019/08/21/fda-expands-tavr-indication-to-low-risk-patients/" title="Read more" >...</a>
Learn about the presentations exhibited during the 10th ProEducar Fellows Course, held in 2019 in the city of Sao Paulo. The course was a real success, as it was attended by more than 150 professionals and renowned international interventionists, such as Doctors Stone, Grines, Granada, Hijazi, Abizaid, Mendiz, Lemos and Leiva Pons. We thank all<a href="https://solaci.org/en/2019/08/15/see-the-presentations-of-the-10-proeducar-fellow-course/" title="Read more" >...</a>